Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma

Published:2020-10-01 Issue:10 Volume:6 Page:1606
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Ravi Praful¹,Mantia Charlene²,Su Christopher³,Sorenson Karl⁴,Elhag Dean⁵,Rathi Nityam⁶,Bakouny Ziad¹,Agarwal Neeraj⁶,Zakharia Yousef⁵,Costello Brian A.⁴,McKay Rana R.⁷,Narayan Vivek⁸,Alva Ajjai³,McGregor Bradley A.¹,Gao Xin⁹,McDermott David F.²,Choueiri Toni K.¹

Affiliation:

1. Dana-Farber Cancer Institute, Boston, Massachusetts

2. Beth Israel Deaconess Medical Center, Boston, Massachusetts

3. University of Michigan, Ann Arbor

4. Mayo Clinic, Rochester, Minnesota

5. The University of Iowa, Iowa City

6. Huntsman Cancer Institute, Salt Lake City, Utah

7. University of California, San Diego

8. University of Pennsylvania, Philadelphia

9. Massachusetts General Hospital, Boston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2766793/jamaoncology_ravi_2020_br_200006_1619718233.41715.pdf

Reference14 articles.

1. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).;Tannir;J Clin Oncol,2020

2. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.;Rini;N Engl J Med,2019

3. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.;Ribas;Lancet Oncol,2015

4. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non–small-cell lung cancer in the KEYNOTE-010 study.;Herbst;J Clin Oncol,2020

5. Nivolumab versus everolimus in advanced renal-cell carcinoma.;Motzer;N Engl J Med,2015

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma;The Lancet;2024-09

2. Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma;Medicine;2024-08-23

3. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review;Cancers;2024-07-20

4. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

5. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer;Cancer Treatment Reviews;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3